Quinn NP - Search Results

1

The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.

Steiger MJ, Stocchi F, Bramante L, Ruggieri S, Quinn NP. Steiger MJ, et al. Among authors: quinn np. Clin Neuropharmacol. 1992 Dec;15(6):501-4. doi: 10.1097/00002826-199212000-00007. Clin Neuropharmacol. 1992. PMID: 1477849

2

Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.

Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn N, Jenner P, Marsden CD, Agnoli A. Stocchi F, et al. Mov Disord. 1992;7(3):249-56. doi: 10.1002/mds.870070311. Mov Disord. 1992. PMID: 1620143 Clinical Trial.

3

The clinical use of apomorphine in Parkinson's disease.

Steiger MJ, Quinn NP, Marsden CD. Steiger MJ, et al. Among authors: quinn np. J Neurol. 1992 Aug;239(7):389-93. doi: 10.1007/BF00812157. J Neurol. 1992. PMID: 1403022

4

The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.

Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD. Steiger MJ, et al. Among authors: quinn np. Clin Neuropharmacol. 1991 Jun;14(3):241-4. doi: 10.1097/00002826-199106000-00007. Clin Neuropharmacol. 1991. PMID: 2070364

5

Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.

Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Marion MH, et al. Among authors: quinn np. Eur Neurol. 1987;27 Suppl 1:54-8. doi: 10.1159/000116193. Eur Neurol. 1987. PMID: 3322837 Clinical Trial.

6

Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.

Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. Marion MH, et al. Among authors: quinn np. Clin Neuropharmacol. 1986;9(2):165-81. doi: 10.1097/00002826-198604000-00008. Clin Neuropharmacol. 1986. PMID: 3708602

7

Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study.

Stocchi F, Quinn NP, Barbato L, Patsalos PN, O'Connel MT, Ruggieri S, Marsden CD. Stocchi F, et al. Among authors: quinn np. Clin Neuropharmacol. 1994 Feb;17(1):38-44. doi: 10.1097/00002826-199402000-00004. Clin Neuropharmacol. 1994. PMID: 8149358 Clinical Trial.

8

The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.

Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F. Schrag AE, et al. Among authors: quinn np. Clin Neuropharmacol. 1998 May-Jun;21(3):169-75. Clin Neuropharmacol. 1998. PMID: 9617508 Clinical Trial.

9

Levodopa challenge test in Parkinson's disease.

Steiger MJ, Quinn NP. Steiger MJ, et al. Among authors: quinn np. Lancet. 1992 Mar 21;339(8795):751-2. doi: 10.1016/0140-6736(92)90658-p. Lancet. 1992. PMID: 1347628 No abstract available.

10

Debrisoquine hydroxylation in Parkinson's disease.

Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PG. Steiger MJ, et al. Among authors: quinn np. Acta Neurol Scand. 1992 Aug;86(2):159-64. doi: 10.1111/j.1600-0404.1992.tb05059.x. Acta Neurol Scand. 1992. PMID: 1414226

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

371 results

Search Page

Filters